UBS Rates Celldex Therapeutics (CLDX) buy, $45 Price Target

UBS Analyst Reaffirms View on Celldex Therapeutics

UBS analyst David Dai has maintained his stance on Celldex Therapeutics, Inc. (NasdaqCM: CLDX), reiterating a buy rating on June 10, 2026, alongside a $45 price target. The update highlights how the firm sees value in the developer of therapeutic antibodies even as shares change hands well below that target level. The biotechnology company focuses on treatments for severe inflammatory and allergic conditions, drawing steady attention from major financial institutions.

Stock Valuation and Market Position

Shares of Celldex recently changed hands at $31.55, sitting below its 50-day moving average of $39.10 while holding above its 200-day moving average of $32.18. The company commands a market capitalization of roughly $2.98 billion. Over the past year, the equity has moved within a 52-week band stretching from a low of $22.10 up to a high of $45.14. Because the firm continues to invest heavily in its clinical pipeline, it does not currently carry a meaningful forward P/E ratio due to negative earnings per share of $4.35.

Wall Street Update and Analyst Coverage

Other major financial houses have also adjusted their outlooks on the biotech firm in recent months. On October 2, 2026, HC Wainwright & Co. reiterated its buy rating with a $64 price target. Earlier in September, Leerink Partners maintained an outperform rating while lifting its target to $88. On the same day, Morgan Stanley kept an overweight rating and raised its target to $57. Cantor Fitzgerald also maintained an overweight rating on September 22, 2026, pushing its target to $72. These views contribute to a consensus recommendation of strong buy across 14 analysts, with a mean price target of $59.07.

Company Background in Biopharmaceuticals

Celldex Therapeutics operates out of Hampton, New Jersey, employing 198 people to advance monoclonal and bispecific antibodies. Its clinical programs target mast cell mediated diseases where current medical options remain inadequate. Key candidates include Barzolvolimab for chronic urticarias and atopic dermatitis, alongside other pipeline assets designed to tackle severe inflammation. The company's scientific progress remains the primary driver behind analyst evaluations and price target adjustments.

What to Watch Next for Shareholders

Investors will look toward the company's next earnings report scheduled for November 9, 2026, for further updates on clinical trials and financial runway. The current quick ratio of 11.71 indicates strong short-term liquidity to support ongoing research and development efforts. As clinical data readouts approach, market participants will continue monitoring whether the stock closes the gap toward existing Wall Street targets.